Marshall Wace, LLP Humacyte, Inc. Transaction History

Marshall Wace, LLP

$81.7 Billion
Q2 2025

A detailed history of Marshall Wace, LLP transactions in Humacyte, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 2,639,194 shares of HUMA stock, worth $3.72 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,639,194

Previous 48,800 5308.18%

Holding current value

$3.72 Million

Previous $83,000 6544.58%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$1.15 - $2.77 $2.98 Million - $7.18 Million	2,590,394 Added 5308.18%	2,639,194 $5.52 Million
Q1 2025 May 15, 2025	SELL	$1.71 - $5.18 $10,460 - $31,686	-6,117 Reduced 11.14%	48,800 $83,000
Q4 2024 Feb 13, 2025	SELL	$3.46 - $5.81 $1.83 Million - $3.08 Million	-529,645 Reduced 90.61%	54,917 $277,000
Q3 2024 Nov 14, 2024	BUY	$5.11 - $9.46 $617,799 - $1.14 Million	120,900 Added 26.08%	584,562 $3.18 Million
Q2 2024 Aug 14, 2024	BUY	$2.87 - $9.1 $1.29 Million - $4.1 Million	450,031 Added 3301.53%	463,662 $2.23 Million
Q1 2024 May 15, 2024	SELL	$2.57 - $4.84 $368,869 - $694,680	-143,529 Reduced 91.33%	13,631 $42,000
Q4 2023 Feb 14, 2024	SELL	$1.99 - $3.12 $37,903 - $59,426	-19,047 Reduced 10.81%	157,160 $446,000
Q3 2023 Nov 14, 2023	BUY	$2.75 - $4.48 $484,569 - $789,407	176,207 New	176,207 $516,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $5.14 $163,116 - $687,228	133,702 Added 227.28%	192,530 $628,000
Q2 2022 Aug 15, 2022	BUY	$3.21 - $7.86 $188,837 - $462,388	58,828 New	58,828 $189,000

Others Institutions Holding HUMA

# of Institutions

171

Shares Held

54.5M

Call Options Held

1.1M

Put Options Held

808K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $145M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Humacyte, Inc. Transaction History